^
Association details:
Biomarker:TMB-H + EGFR mutation
Cancer:Non Small Cell Lung Cancer
Drug Class:PD-L1 inhibitor
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Acquired resistance to PD-1 blockade in NSCLC.

Published date:
05/13/2020
Excerpt:
We retrospectively collected data for patients with unresectable stage III NSCLC harboring EGFR mutations...All patients with NSCLC treated with PD-1 blockade at MSKCC were examined….Patients with PD-L1 expression < 50% and TMB < 8mut/Mb were more likely to develop resistance compared those with PD-L1 expression ≥50% and TMB ≥8mut/Mb (OR 5.5, p = 0.02).
DOI:
10.1200/JCO.2020.38.15_suppl.9621